Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016-05-10
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.
Related Questions
What is the goal of estradiol levels on ovarian suppression and AI for breast cancer?
This is a sneaky difficult question. We've known since George Beatson that estrogen was important for breast cancer, and the Early Breast Cancer Trialists Collaborative Group helped get Tamoxifen approved in 1978. I've heard it said that we've had more trials looking at estrogen therapy for breast c...
How would you approach a postmenopausal female with localized ER+ breast cancer on adjuvant anastrozole with a rising estradiol level?
First, I do not usually check estradiol levels in my patients on an aromatase inhibitor, in part because many of the available estradiol assays are not very accurate, and because the AIs are so effective at blocking estrogen production. However, now that you have this value, the first thing I would ...
How do you monitor ovarian function in high risk, premenopausal breast cancer patients receiving adjuvant ovarian suppression?
Great question. Extremely clinically relevant. Here's the problem with 'medical oophorectomy': ABCSG-12 showed that OFS+AI in premenopausal women who were overweight had a 50% increased risk for disease recurrence. SOFT trial sub-study, SOFT-EST, showed that one in three women on OFS+AI have subopti...